NCT05199311View on ClinicalTrials.gov

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Carfilzomib

20 mg/m2 C1D1; 56 mg/m2 thereafter

DRUG

Iberdomide

Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle

DRUG

Oral Dexamethasone

40 mg (\<=75 years old); 20 mg (\>75 years old)

Trial Locations (2)

20007

RECRUITING

Lombardi Comprehensive Cancer Center, Washington D.C.

07601

RECRUITING

John Theurer Cancer Center, Hackensack

All Listed Sponsors
lead

Hackensack Meridian Health

OTHER